UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Antimicrobial agents and chemotherapy, ISSN 0066-4804, 01/2016, Volume 60, Issue 1, pp. 252 - 257
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Microbiology | Science & Technology | Coinfection | Humans | Gram-Positive Bacterial Infections - mortality | Bacteremia - mortality | Male | Enterococcus - growth & development | Clostridium Infections - microbiology | Cross Infection - pathology | Gram-Positive Bacterial Infections - microbiology | Candidiasis - pathology | Clostridium Infections - mortality | Odds Ratio | Enterobacteriaceae - growth & development | Enterobacteriaceae Infections - microbiology | Risk Factors | Bacteremia - drug therapy | Cross Infection - drug therapy | Gram-Positive Bacterial Infections - pathology | Candida - pathogenicity | Vancomycin - therapeutic use | Cross Infection - microbiology | Enterobacteriaceae - drug effects | Enterococcus - pathogenicity | Survival Analysis | Clostridium Infections - drug therapy | Enterococcus - drug effects | Gram-Positive Bacterial Infections - drug therapy | Bacteremia - pathology | Clostridium difficile - drug effects | Enterobacteriaceae Infections - drug therapy | Multivariate Analysis | Cross Infection - mortality | Candidiasis - microbiology | Case-Control Studies | Bacteremia - microbiology | Clostridium Infections - pathology | Candidiasis - drug therapy | Metronidazole - therapeutic use | Female | Candida - growth & development | Enterobacteriaceae - pathogenicity | Enterobacteriaceae Infections - mortality | Anti-Infective Agents - therapeutic use | Candidiasis - mortality | Treatment Outcome | Enterobacteriaceae Infections - pathology | Clostridium difficile - pathogenicity | Clostridium difficile - growth & development | Aged | Candida - drug effects | Index Medicus
Journal Article
The Lancet infectious diseases, ISSN 1473-3099, 2017, Volume 17, Issue 9, pp. 990 - 1001
Infectious Disease | Life Sciences & Biomedicine | Infectious Diseases | Science & Technology | Bacterial Infections - drug therapy | Cross Infection - prevention & control | Gram-Negative Bacteria | Humans | Drug Resistance, Bacterial | Practice Patterns, Physicians | Clostridium Infections - epidemiology | Clostridium difficile - isolation & purification | Clostridium Infections - prevention & control | Cross Infection - drug therapy | Incidence | Methicillin-Resistant Staphylococcus aureus | Anti-Bacterial Agents - therapeutic use | Bacterial Infections - prevention & control | beta-Lactamases | Clostridium Infections - drug therapy | Cross Infection - epidemiology | Medical research | Drug resistance in microorganisms | Analysis | Long-term care of the sick | Medicine, Experimental | Bacteria | Health aspects | Antibacterial agents | Medical care, Cost of | Intervention | Clinical trials | Systematic review | Long term health care | Infections | Vancomycin | Drug resistance | Clinical outcomes | Methicillin | Literature reviews | Heterogeneity | Audits | E coli | Antibiotic resistance | Aminoglycoside antibiotics | Gram-negative bacteria | Bacterial infections | Hospital costs | Staphylococcus infections | Long-term care | Meta-analysis | Studies | Antibiotics | Hygiene | Colonization | Index Medicus
Journal Article
Clinical infectious diseases, ISSN 1058-4838, 9/2011, Volume 53, Issue 5, pp. 440 - 447
Clostridium | Health outcomes | Infectious diseases | Antibiotics | Clostridium difficile | Penicillin | Diarrhea | Infections | Colitis | ARTICLES AND COMMENTARIES | Dosage | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Stomach. Duodenum. Small intestine. Colon. Rectum. Anus | Bacterial diseases of the digestive system and abdomen | Bacterial diseases | Human bacterial diseases | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Antibacterial agents | Other diseases. Semiology | Antibiotics. Antiinfectious agents. Antiparasitic agents | Humans | Middle Aged | Male | Enterocolitis, Pseudomembranous - etiology | Young Adult | Anti-Bacterial Agents - therapeutic use | Enterocolitis, Pseudomembranous - drug therapy | Vancomycin - therapeutic use | Adolescent | Aged, 80 and over | Adult | Female | Aged | Anti-Bacterial Agents - adverse effects | Drug Therapy, Combination | Aminoglycosides - therapeutic use | Clostridium infections | Patient outcomes | Fidaxomicin | Dosage and administration | Research | Vancomycin | Drug therapy | Clinical trials | Side effects | Bacterial infections | Effectiveness studies | Index Medicus | and Commentaries
Journal Article
Expert review of anti-infective therapy, ISSN 1478-7210, 02/2016, Volume 14, Issue 2, pp. 193 - 206
colonisation | infection | gastroenteritis | Clostridium difficile | Antimicrobial therapy | GI tract | diarrhoea | resistance | Pharmacology & Pharmacy | Infectious Diseases | Life Sciences & Biomedicine | Microbiology | Science & Technology | Campylobacter Infections - diagnosis | Humans | Salmonella Infections - diagnosis | Gastroenteritis - drug therapy | Anti-Bacterial Agents - therapeutic use | Rifamycins - therapeutic use | Cholera - drug therapy | Campylobacter Infections - drug therapy | Enterocolitis, Pseudomembranous - diagnosis | Escherichia coli Infections - drug therapy | Salmonella Infections - drug therapy | Acute Disease | Escherichia coli Infections - diagnosis | Dysbiosis - chemically induced | Bacterial Infections - drug therapy | Cholera - diagnosis | Ciprofloxacin - therapeutic use | Dysentery, Bacillary - diagnosis | Yersinia Infections - drug therapy | Dysentery, Bacillary - drug therapy | Yersinia Infections - diagnosis | Enterocolitis, Pseudomembranous - drug therapy | Azithromycin - therapeutic use | Shiga-Toxigenic Escherichia coli | Diarrhea - drug therapy | Bacterial Infections - diagnosis | Aminoglycosides - therapeutic use | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 02/2011, Volume 364, Issue 5, pp. 422 - 431
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Stomach. Duodenum. Small intestine. Colon. Rectum. Anus | General aspects | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Antibacterial agents | Other diseases. Semiology | Antibiotics. Antiinfectious agents. Antiparasitic agents | Clostridium difficile - classification | Prospective Studies | Humans | Middle Aged | Male | Secondary Prevention | Clostridium difficile - isolation & purification | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Feces - microbiology | Adult | Female | Anti-Bacterial Agents - adverse effects | Aminoglycosides - pharmacokinetics | Double-Blind Method | Treatment Outcome | Vancomycin - adverse effects | Enterocolitis, Pseudomembranous - drug therapy | Vancomycin - pharmacokinetics | Vancomycin - therapeutic use | Anti-Bacterial Agents - pharmacokinetics | Intention to Treat Analysis | Clostridium Infections - drug therapy | Aged | Aminoglycosides - adverse effects | Clostridium difficile - drug effects | Aminoglycosides - therapeutic use | Vancomycin | Antibiotics | Clostridium infections | Comparative analysis | Drug therapy | Health aspects | Clinical trials | Infections | Manuscripts | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Infection control and hospital epidemiology, ISSN 0899-823X, 05/2010, Volume 31, Issue 5, pp. 431 - 455
Public, Environmental & Occupational Health | Infectious Diseases | Life Sciences & Biomedicine | Science & Technology | Enterocolitis, Pseudomembranous - epidemiology | Humans | Clostridium Infections - epidemiology | Infection Control - methods | Cross Infection - drug therapy | Enterocolitis, Pseudomembranous - drug therapy | Cross Infection - diagnosis | Adult | Clostridium Infections - drug therapy | Enterocolitis, Pseudomembranous - diagnosis | Clostridium Infections - diagnosis | Clostridium difficile - drug effects | Cross Infection - epidemiology | Index Medicus | Nursing
Journal Article
JAMA internal medicine, ISSN 2168-6106, 03/2015, Volume 175, Issue 5, pp. 784 - 791
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Age Factors | Cross Infection - etiology | Humans | Middle Aged | Inappropriate Prescribing - statistics & numerical data | Clostridium Infections - etiology | Male | Inappropriate Prescribing - prevention & control | Clostridium Infections - epidemiology | Secondary Prevention - methods | Incidence | Anti-Bacterial Agents - therapeutic use | Canada - epidemiology | Clostridium Infections - physiopathology | Female | Retrospective Studies | Clostridium Infections - therapy | Clostridium Infections - diagnosis | Length of Stay - statistics & numerical data | Cross Infection - epidemiology | Cross Infection - therapy | Inappropriate Prescribing - adverse effects | Cross Infection - physiopathology | Risk Factors | Proton Pump Inhibitors - therapeutic use | Withholding Treatment | Secondary Prevention - statistics & numerical data | Anti-Bacterial Agents - classification | Cross Infection - diagnosis | Aged | Clostridium difficile - drug effects | Complications and side effects | Care and treatment | Relapse | Clostridium infections | Proton pump inhibitors | Dosage and administration | Risk factors | Diseases | Index Medicus | Abridged Index Medicus
Journal Article